Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -1.03% from its latest closing price compared to the recent 1-year high of $13.71. Akebia Therapeutics, Inc. (NASDAQ:AKBA)’s stock price shot up 6.6% during mid-day trading on Monday . Shares of Akebia Therapeutics (NASDAQ:AKBA) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from a … Copyright 2019© FactSet Research Systems Inc. All rights reserved. Further, Akebia Therapeutics, Inc. (AKBA) has a beta value of 1.94, and an average true range (ATR) of 0.26. The company’s stock price has collected 13.39% of gains in the last five trading sessions. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. A high-level overview of Akebia Therapeutics, Inc. (AKBA) stock. Find the latest press releases from Akebia Therapeutics, Inc. Common Stock (AKBA) at Nasdaq.com. Simply Wall St. Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Are … International stock quotes are delayed as per exchange requirements. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Akebia Therapeutics (AKBA) Gets a Buy Rating from Mizuho Securities, Needham Releases a Buy Rating on Akebia Therapeutics (AKBA), Akebia Therapeutics (AKBA) Reports Q3 Loss, Lags Revenue Estimates, Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release, Seth Klarman Axes Akebia Therapeutics Stake From Portfolio, Akebia Therapeutics (AKBA) Looks Good: Stock Adds 6.7% in Session. Visit a quote page and your recently viewed tickers will be displayed here. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Get Our PREMIUM Forecast Now, from ONLY $6.69! Privacy Notice, and Dow sinks 272 points, but books best November since 1928, and best month since ’87, Arizona, Wisconsin certify election win for Biden, New York zeroes in on hospitals as COVID-19 cases climb, K12 paying ransom to cybercriminals following breach, Tesla stock to be added all at once to S&P 500, Powell says Fed actions unlocked $2 trillion to support economy, Zoom Stocks Falls Despite Another Earnings Blowout, Akebia Therapeutics stock price target cut to $6 from $17 at Mizuho, Akebia Therapeutics started at overweight with $12 stock price target at J.P. Morgan, Akebia Therapeutics started at outperform with $18 stock price target at Raymond James, Akebia and Keryx expect deal to close by year-end, Akebia and Keryx say deal will create company with pro forma equity value of about $1.3 bln, Akebia Therapeutics and Keryx Biopharmaceuticals to merge in all-stock deal, Akebia Therapeutics' stock soars 78% to lead Nasdaq gainers after positive trial results, Akebia's shares jump on late-stage clinical trial results for kidney disease drug, Akebia shares jump on expanded anemia drug deal with Otsuka, Akebia Shares Could More Than Double in a Year. For the best MarketWatch.com experience, please update to a modern browser. Do Options Traders Know Something About Akebia (AKBA) Stock We Don't? Have Watchlists? Something went wrong while loading Watchlist. Akebia Therapeutics, Inc. Common Stock (AKBA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. Copyright © 2020 MarketWatch, Inc. All rights reserved. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. Needham’s estimates were contained in a research note released on Thursday, November 14, 2019. Akebia Therapeutics, Inc. (AKBA) Shares March Higher, Can It Continue? The Investor Relations website contains information about Akebia Therapeutics's business for stockholders, potential investors, and financial analysts. The company traded as high as $3.18 and last traded at $3.07. Investors in Akebia Therapeutics (NASDAQ:AKBA), Inc. AKBA need to pay close attention to the stock based on moves in the options market lately.
2020 akebia therapeutics stock